Parkinson’s disease is marked by the death of dopamine-producing neurons in a small midbrain area called the substantia nigra, which is what produces the classic tremors, slowness and rigidity. Why those particular neurons die isn’t fully settled, but the research has moved well beyond “dopamine runs low.” Several threads now point in the same direction: a toxic by-product of dopamine’s own breakdown called DOPAL, a protein called alpha-synuclein that misfolds and clumps, and growing evidence that the whole process may begin years earlier in the gut. None of these is the complete answer on its own — but together they paint a far richer picture than dopamine deficiency alone, and one where prevention-minded questions become worth asking.
What actually happens in Parkinson’s
Deep in the midbrain, within the basal ganglia, sits the substantia nigra — a small cluster of dopamine-releasing neurons that feed dopamine to a neighbouring region called the striatum to coordinate movement.
In Parkinson’s, these neurons progressively die. As dopamine signalling to the striatum breaks down, movement control unravels, producing the recognisable features: resting tremor, slowed movement (bradykinesia), and muscle rigidity. By the time these motor symptoms appear, a large proportion of the substantia nigra’s dopamine neurons have already been lost — which is part of why the disease is so hard to catch early, and why the question of what kills those neurons in the first place matters so much.
Dopamine’s own breakdown can turn toxic: the catecholaldehyde hypothesis
This is the mechanism that most reframes how to think about Parkinson’s, and it’s worth understanding because it’s counterintuitive: under the wrong conditions, the breakdown of dopamine itself produces a toxin.
When dopamine is metabolised inside the neuron, an enzyme called monoamine oxidase (MAO) converts it into a compound called DOPAL (3,4-dihydroxyphenylacetaldehyde)¹. DOPAL is highly reactive and genuinely toxic — but in a healthy neuron it exists only briefly, because a second enzyme, aldehyde dehydrogenase (ALDH), rapidly converts it into DOPAC (3,4-dihydroxyphenylacetic acid), which is safe and easily cleared¹ ².
So the sequence is: dopamine → DOPAL (toxic, transient) → DOPAC (safe). The critical step is ALDH doing its job. When ALDH can’t keep up — through genetics, ageing, or something inhibiting it — DOPAL accumulates instead of being cleared².
And accumulated DOPAL does real damage. It cross-links with proteins and drives oxidative injury, and crucially it triggers alpha-synuclein to clump together into the toxic forms found in Parkinson’s³. In animal studies, injecting DOPAL selectively kills the dopamine neurons of the substantia nigra while sparing neighbouring cells, and mice engineered to lack ALDH develop a Parkinson’s-like condition with DOPAL buildup and neuron death⁴. This framework — that a toxic dopamine metabolite drives the disease — is called the catecholaldehyde hypothesis, and it’s one of the more compelling accounts of why these specific neurons are so vulnerable² ⁵.
It’s worth being clear on status: this is a leading, well-supported hypothesis with strong experimental backing, not a closed case. But it shifts the question in a useful way — from “how do we replace lost dopamine” to “why is dopamine’s own clearance pathway failing, and what interferes with it.”
Where pesticides fit — and it connects directly to DOPAL
Parkinson’s has long been linked with pesticide exposure, and the catecholaldehyde hypothesis explains one route by which that link may work — tying two apparently separate risk factors into one mechanism.
Some pesticides inhibit ALDH, the very enzyme responsible for clearing DOPAL. The fungicide benomyl is the best-studied example: it potently blocks ALDH, causing DOPAL to build up, and exposure has been associated with increased Parkinson’s risk⁶. So “pesticides increase Parkinson’s risk” and “DOPAL buildup kills dopamine neurons” aren’t two separate stories — for some chemicals, they’re the same story. The pesticide causes harm precisely by sabotaging DOPAL clearance⁶.
This doesn’t mean every pesticide works this way, or that pesticide exposure is the main cause of Parkinson’s — the disease is multifactorial. But it’s a clear, mechanistic example of how an environmental exposure can feed directly into the neuron’s own chemistry.
Alpha-synuclein: the protein that misfolds
Alpha-synuclein is a normal, soluble protein found in healthy nerve cells, where it helps regulate dopamine release and interacts with cell membranes. It’s encoded by the SNCA gene.
In Parkinson’s, alpha-synuclein misfolds and aggregates into clumps — the main component of the Lewy bodies that are a hallmark of the disease. These aggregates are toxic to neurons, and they accumulate in the substantia nigra among other regions³ ⁵.
What connects this back to the previous section is striking: DOPAL is one of the things that drives alpha-synuclein to oligomerise in the first place, and those alpha-synuclein clumps in turn impair the neuron’s ability to package and handle dopamine safely — which pushes still more dopamine down the toxic DOPAL route⁵. It becomes a self-reinforcing loop: DOPAL damages the protein, the damaged protein generates more DOPAL. That vicious cycle is part of why the neurodegeneration, once established, is so relentless.
There’s also an overlap with Alzheimer’s worth noting: a fragment of alpha-synuclein has been found within the amyloid plaques of Alzheimer’s disease, one of several hints that different neurodegenerative diseases may share underlying mechanisms while expressing differently — shaped by genetics and other factors into distinct conditions.
The gut connection — promising, and still being established
One of the most active areas of Parkinson’s research is the idea that the disease may begin, for many people, not in the brain but in the gut.
The observations behind this are genuinely intriguing. People who develop Parkinson’s very often have gut symptoms — constipation in particular — for years, sometimes up to a decade, before any motor symptoms appear⁷. Alpha-synuclein aggregates, the same kind found in the Parkinson’s brain, have been found in the nerves of the gut in these patients⁷. And research has increasingly linked the make-up of the gut microbiome to Parkinson’s, with animal work suggesting gut bacteria can influence the motor symptoms and neuroinflammation of the disease⁸.
The leading idea — sometimes called the “gut-first” model — is that misfolded alpha-synuclein may originate in the gut and travel to the brain via the vagus nerve. It’s a compelling hypothesis with accumulating support, but it’s important to be honest that it’s still being established rather than proven, and it likely describes some cases better than others⁷ ⁸.
What’s reasonable to take from it: gut health is plausibly relevant to this disease in a way it wasn’t thought to be a generation ago, and the gut may offer an early window — those years of preceding gut symptoms — long before the brain shows its hand.
Does gut trouble or a gene mean you’ll get Parkinson’s? No.
This needs saying plainly, because the mechanisms above can read as alarming. Constipation does not mean Parkinson’s is coming. Gut dysbiosis is common and Parkinson’s is not. A single gene variant does not seal anyone’s fate.
Parkinson’s is multifactorial — it emerges from a combination of genetic susceptibility, environmental exposures, ageing and, very likely, chance, interacting over decades. The mechanisms described here are pieces of a puzzle that only assembles into disease in a minority of people, under the wrong combination of circumstances. Understanding them is useful for thinking about risk and resilience, not for self-diagnosis.
Genetics: COMT and the honest picture
Because dopamine is a catechol, the enzymes that handle catechols are naturally of interest. COMT (catechol-O-methyltransferase) is one — it breaks down catechol compounds including dopamine, adrenaline, noradrenaline and oestrogen, and a common variant (rs4680) makes the enzyme faster or slower.
You’ll see COMT variants linked to Parkinson’s in some places, but here honesty is warranted: the genetic association between COMT rs4680 and Parkinson’s risk is inconsistent across studies rather than established. Some analyses suggest a link, particularly in interaction with medication response; others find none. So COMT is genuinely relevant to how a person processes dopamine and catechols — which can matter for how they respond to things — but it should not be presented as a confirmed Parkinson’s risk gene. It’s one factor of interest among many, not a verdict.
This fits the broader theme: single genes rarely determine complex diseases. What genetic variants more usefully indicate is where an individual’s biochemistry may be more vulnerable under load — a tendency, not a destiny.
How gut bacteria can disrupt dopamine directly
There’s one more thread that connects the gut and dopamine mechanistically, and it’s measurable.
Certain gut bacteria produce phenolic compounds that are structurally similar to the body’s own catechols, which puts them in a position to interfere with catecholamine chemistry. A well-known example is 4-cresol (para-cresol), a compound produced by some gut bacteria that can interfere with the enzyme dopamine beta-hydroxylase, which converts dopamine into noradrenaline — disturbing the normal balance. (Worth noting: 4-cresol is produced by a range of tyrosine-fermenting gut bacteria, not one organism, so it points to a pattern rather than a single culprit.)
This matters practically because these dopamine-related metabolites — including DOPAC, and markers of bacterial compounds like 4-cresol — can be measured in urine through an Organic Acid Test. That doesn’t diagnose or predict Parkinson’s, and it shouldn’t be read that way. But it can offer a window into how someone’s dopamine metabolism and gut-derived interference are running — which is information, read as a pattern alongside everything else, rather than a single alarming number.
What this means for looking after yourself
None of this is medical advice, and Parkinson’s is a serious neurological condition that belongs firmly with medical specialists. But the mechanisms do point toward some reasonable, low-risk principles for general brain and metabolic resilience:
- Gut health is plausibly relevant. Given the gut’s emerging role, supporting a healthy microbiome is a sensible foundation — as it is for most chronic conditions.
- Minimise avoidable pesticide exposure where practical, given the ALDH-inhibition link. This is about reducing an identifiable burden, not panic.
- Support the body’s general antioxidant and detoxification capacity, since DOPAL toxicity works partly through oxidative stress — the same broad principles that help the body handle any reactive burden.
- Take early, persistent gut symptoms seriously in their own right — not as a Parkinson’s predictor, but because gut health matters regardless.
The value in understanding these mechanisms isn’t to worry about a disease that most people will never develop. It’s that they reframe neurodegeneration as something with upstream, biochemical contributors — dopamine clearance, gut health, oxidative burden — rather than a purely random fate, and those upstream factors are where general resilience is built.
The short version
Parkinson’s involves the death of dopamine neurons in the substantia nigra, but the “why” is richer than dopamine deficiency. A toxic by-product of dopamine’s own breakdown, DOPAL, builds up when the clearing enzyme ALDH can’t keep pace — and it damages neurons and misfolds alpha-synuclein, in a self-reinforcing loop that some pesticides feed by blocking ALDH. Meanwhile, evidence increasingly suggests the process may begin in the gut years before the brain shows symptoms. None of these is the whole story, and none means an individual is destined for the disease — but together they point to real, upstream factors worth understanding.
Frequently asked questions
What causes the neuron death in Parkinson’s disease?
It isn’t fully settled, but leading mechanisms include the buildup of a toxic dopamine by-product called DOPAL when the clearing enzyme ALDH underperforms, the misfolding and clumping of the protein alpha-synuclein, oxidative stress, and possibly a process that begins in the gut. These interact rather than acting alone.
What is the catecholaldehyde hypothesis?
The idea that a toxic intermediate of dopamine metabolism, DOPAL, drives the death of dopamine neurons in Parkinson’s. Dopamine is broken down into DOPAL, which is normally quickly detoxified into harmless DOPAC by the enzyme ALDH. When ALDH can’t keep up, DOPAL accumulates and damages neurons.
Is DOPAC harmful?
No — DOPAC is the safe end-product. The harmful compound is DOPAL, the step before it. The body converts toxic DOPAL into safe DOPAC using the enzyme ALDH. The problem arises when that conversion fails and DOPAL builds up instead.
How are pesticides linked to Parkinson’s?
One route is that certain pesticides inhibit ALDH, the enzyme that clears the toxic dopamine metabolite DOPAL. Blocking it lets DOPAL accumulate. The fungicide benomyl is a well-studied example. This connects pesticide exposure directly to the disease’s internal chemistry, though it’s one factor among many.
Does gut health affect Parkinson’s disease?
Evidence increasingly suggests it may. People who develop Parkinson’s often have gut symptoms like constipation for years beforehand, alpha-synuclein aggregates have been found in the gut, and the microbiome has been linked to the disease. The “gut-first” model is promising but still being established, not proven.
If I have gut problems or a gene variant, will I get Parkinson’s?
No. Parkinson’s is multifactorial — it requires a combination of genetic susceptibility, environmental exposure, ageing and chance interacting over decades. Gut problems are common and a single gene variant is not a verdict. These mechanisms describe risk and biology, not destiny.
References
- Dopamine is metabolised by monoamine oxidase (MAO) to DOPAL, which is then converted by aldehyde dehydrogenase (ALDH) to the much less reactive DOPAC. Masato et al. (2019), Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Molecular Neurodegeneration, 14:35.
- DOPAL is a highly reactive, toxic catabolite; decreased ALDH activity causes DOPAL buildup, which is elevated relative to dopamine in Parkinson’s brains. Goldstein, D. S. et al. (2013). Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. Journal of Neurochemistry, 126, 591–603.
- DOPAL cross-links proteins, drives oxidative injury and induces alpha-synuclein oligomerisation; DOPAL-derived oligomers damage synaptic vesicles. Plotegher, N. et al. (2017), Scientific Reports, 7:40699.
- Intracerebral DOPAL selectively kills substantia nigra dopaminergic neurons in vivo; ALDH-knockout mice show a Parkinsonian phenotype with DOPAL accumulation. Panneton, W. M. et al. (2010), PLoS ONE, PMC3001493.
- The catecholaldehyde hypothesis and the self-reinforcing DOPAL–alpha-synuclein cycle in catecholaminergic neurodegeneration. Goldstein, D. S. (2021), International Journal of Molecular Sciences, PMC8199574.
- The fungicide benomyl inhibits ALDH and builds up DOPAL in vivo; ALDH-inhibiting pesticide exposure may increase Parkinson’s risk. Fitzmaurice et al. / Chemical Research in Toxicology (2014), “Benomyl, Aldehyde Dehydrogenase, DOPAL, and the Catecholaldehyde Hypothesis.”
- Gut symptoms such as constipation can precede motor Parkinson’s by years; alpha-synuclein aggregates are found in enteric nerves, supporting a proposed gut-to-brain “gut-first” model via the vagus nerve. Reviewed in gut-brain Parkinson’s literature (2019–).
- Sampson, T. R. et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell, 167(6), 1469–1480.
